Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study
Research article
[키워드] 95% CI
acute respiratory syndrome
Anticoagulants
Antigen
association
Asymptomatic
Benign
biochemical marker
Biomarker
CD40 ligand
clinical outcomes
Coagulation factors
Coagulopathy
Comparator group
complications
Concentration
Control
controls
coronavirus
correlated
correlation
COVID-19
Critical
cross-sectional
death
determine
elevated
Endothelial cell
endotheliopathy
Enzymes
Evidence
Factor
fibrinolytic
finding
funding
greater
hazard ratio
hematology
hospital
hospital discharge
hospitalised
ICU
ICU patient
ICU Patients
IMPROVE
Injury
intensive care
involved
Kaplan–Meier analysis
laboratory result
laboratory-confirmed
likelihood
marker
mitigate
Mortality
non-critically ill patient
non-hospitalised
non-ICU
non-ICU patients
outcome
P-selectin
Pathogenesis
Patient
patients
patients with COVID-19
platelet activation
previous study
progression
recruited
significantly
suggested
supported
survival
thrombotic
vWF
was used
with COVID-19
[DOI] 10.1016/S2352-3026(20)30216-7 [Article Type] Research article
[DOI] 10.1016/S2352-3026(20)30216-7 [Article Type] Research article